Note: This document contains side effect information about hyaluronidase / immune globulin. Some dosage forms listed on this page may not apply to the brand name Hyqvia.
Summary
More frequent side effects include: fever, nausea, and vomiting. Continue reading for a comprehensive list of adverse effects.
Applies to hyaluronidase / immune globulin: subcutaneous solution.
Warning
Subcutaneous route (Kit)
Warning: ThrombosisThrombosis may occur with immune globulin products, including immune globulin/recombinant human hyaluronidase. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.For patients at risk of thrombosis, administer immune globulin/recombinant human hyaluronidase at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
Serious side effects of Hyqvia
Along with its needed effects, hyaluronidase / immune globulin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking hyaluronidase / immune globulin:
More common
- Fever
Other side effects of Hyqvia
Some side effects of hyaluronidase / immune globulin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Headache
- nausea
- red streaks on the skin
- swelling, tenderness, or pain at the injection site
- unusual tiredness or weakness
- vomiting
Less common
- Itching, redness, swelling, discomfort, or pain at the injection site
For Healthcare Professionals
Applies to hyaluronidase / immune globulin: subcutaneous solution.
General
The most common adverse events were local reactions, headache, antibody formation against recombinant human hyaluronidase (rHuPH20), fatigue, nausea, pyrexia, and vomiting.[Ref]
Local
Very common (10% or more): Local reaction (51.9%)
Frequency not reported: Local pain and swelling, discomfort/pain, erythema, pruritus[Ref]
Nervous system
Very common (10% or more): Headache (21%), fatigue (11.1%)
Postmarketing reports: Transient ischemic attack, tremor, burning sensation, cerebrovascular accident, coma, seizures, loss of consciousness[Ref]
Immunologic
Very common (10% or more): Antibodies to recombinant human hyaluronidase (18%)[Ref]
Other
Very common (10% or more): Systemic adverse reaction (67.9%)
Common (1% to 10%): Pyrexia
Frequency not reported: Fever, back injury, transient swelling from abdominal infusion site to genitalia
Postmarketing reports: Edema, rigors[Ref]
Gastrointestinal
Common (1% to 10%): Nausea, vomiting
Postmarketing reports: Abdominal pain[Ref]
Hematologic
Frequency not reported: Acute intravascular hemolysis
Postmarketing reports: Leukopenia, pancytopenia[Ref]
Renal
Frequency not reported: Acute renal dysfunction/failure[Ref]
Cardiovascular
Postmarketing reports: Hypotension, hypertension, myocardial infarction, chest pain, cardiac arrest, vascular collapse[Ref]
Respiratory
Postmarketing reports: Pulmonary edema, dyspnea, oxygen saturation decreased, cyanosis, hypoxemia, bronchospasm, apnea, acute respiratory distress syndrome (ARDS)[Ref]
Dermatologic
Postmarketing reports: Hyperhidrosis, allergic dermatitis, bullous dermatitis, epidermolysis, erythema multiforme, Stevens-Johnson Syndrome[Ref]
Hepatic
Postmarketing reports: Hepatic dysfunction[Ref]
Psychiatric
Postmarketing reports: Anxiety, insomnia[Ref]
Musculoskeletal
Postmarketing reports: Back pain[Ref]
